Detalles de la búsqueda
1.
Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP.
Oncologist
; 26(7): 597-609, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33870594
2.
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.
Ann Hematol
; 100(9): 2279-2292, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33523289
3.
The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Hematol Oncol
; 36(4): 693-700, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30129144
4.
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
Blood
; 126(11): 1392-4, 2015 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26359434
5.
Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.
In Vivo
; 36(3): 1302-1315, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35478115
6.
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.
Ther Adv Hematol
; 11: 2040620720966121, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33343854
7.
Increased age-associated B cells in patients with acquired aplastic anemia correlate with IFN-γ.
Blood Adv
; 8(2): 399-402, 2024 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38011610
8.
Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?
Leukemia
; 37(12): 2517-2519, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37816955
9.
Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis.
Leuk Lymphoma
; 47(8): 1553-6, 2006 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16966266
10.
Prognostic value of serum beta2-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment.
Clin Lymphoma Myeloma
; 7(3): 205-9, 2006 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17229336
11.
Correlation of SIN3A genomic variants with ß-hemoglobinopathies disease severity and hydroxyurea treatment efficacy.
Pharmacogenomics
; 17(16): 1785-1793, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27767389
12.
Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/ß-thalassemia patients.
Pharmacogenomics
; 17(4): 393-403, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26895070
13.
Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
J Geriatr Oncol
; 11(1): 121-124, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31362867
14.
The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia.
Leuk Lymphoma
; 45(9): 1809-13, 2004 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15223640
15.
Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group.
Leuk Res
; 71: 55-59, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30007218
16.
Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH).
Leuk Res
; 34(10): 1340-3, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20447689
17.
Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
J Clin Oncol
; 25(22): 3344-9, 2007 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17577016
18.
Multiple myeloma in elderly patients: prognostic factors and outcome.
Eur J Haematol
; 75(5): 370-5, 2005 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16191085
19.
Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients.
Br J Haematol
; 118(1): 174-80, 2002 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12100145
20.
Prognostic significance of deletion of the long arm of chromosome 20 in patients with myelodysplastic syndrome (MDS): a study of the Greek MDS Study Group.
Eur J Haematol
; 78(1): 89-90, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17302860
Resultados
1 -
20
de 20
1
Próxima >
>>